About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/04/2020.
Our Science
  • Fedratinib (JAK2 Inhibitor)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Proposed Mechanism of Action

    Fedratinib is an oral small molecule kinase inhibitor with higher selectivity for JAK2 over other JAK family members, including JAK1, JAK3 and tyrosine kinase 2.1-3 Myelofibrosis is a life-threatening myeloproliferative neoplasm (MNP) that occurs due to the proliferation of mutant hematopoietic stem and progenitor cells and can be caused by alterations in the JAK/STAT pathway.4,5 Approximately 60–65% of patients with primary myelofibrosis have a mutation in JAK2, typically JAK2V617F.5 An additional 20-30% of patients with primary myelofibrosis have abnormalities in markers mutant Calreticulin or the thrombopoietin receptor, also known as the myeloproliferative leukemia protein (MPL), which also signal through the JAK2/STAT pathway.5 Preclinical studies have suggested that fedratinib may inhibit both mutant and wild-type JAK2, thus blocking abnormal hyperactive JAK/STAT signaling and inhibiting proliferation in hematopoietic stem cells with or without mutations in JAK2.2,6,7

    Fedratinib Proposed Mechanism of Action

    Used under license, ©2019 Impact Biomedicines, Inc.

    Fedratinib by Disease State

    Fedratinib in Myelofibrosis

    Phase 3
    Myelofibrosis

    View Trials Investigating Fedratinib in Myelofibrosis
    View Rationale for Clinical Development

    Rationale for Clinical Development

    Preclinical studies using mouse models of JAK2V617F-driven myeloproliferative disease have suggested that fedratinib blocked phosphorylation of STAT 3/5 and improved survival, white blood cell counts, hematocrit, splenomegaly, and fibrosis, supporting the clinical development of fedratinib in myelofibrosis.1

    View Related Pathways

    References

    1. Inrebic (fedratinib) [package insert]. Summit, NJ: Celgene Corporation; 2019.
    2. Wernig G, et al. Cancer Cell. 2008;13:311-320. PMID: 18394554
    3. Zhou T, et al. Leukemia. 2014;28:404-407. PMID: 23823659
    4. Teferri A. Am J Hematol. 2016;91:1262-1271. PMID: 27870387
    5. Cazzola M and Kralovics R. Blood. 2014;123:3714-3719. PMID: 24786775
    6. Lim KH, et al. Blood Cancer J. 2016;6:e481. PMID: 27716741
    7. Lasho TL, et al. Leukemia. 2008;22:1790-1792. PMID: 18354492